BR0108344A - Modulação de formação óssea - Google Patents

Modulação de formação óssea

Info

Publication number
BR0108344A
BR0108344A BR0108344-9A BR0108344A BR0108344A BR 0108344 A BR0108344 A BR 0108344A BR 0108344 A BR0108344 A BR 0108344A BR 0108344 A BR0108344 A BR 0108344A
Authority
BR
Brazil
Prior art keywords
bone
bone formation
ligand
deposition
formation modulation
Prior art date
Application number
BR0108344-9A
Other languages
English (en)
Inventor
Andrew Scutt
Karen Still
Original Assignee
Univ Sheffield
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Sheffield filed Critical Univ Sheffield
Publication of BR0108344A publication Critical patent/BR0108344A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

"MODULAçãO DE FORMAçãO óSSEA". O uso de um ativador ou ligando de um receptor ativado por prolífero de peroxissoma, diferente de PPAR<sym>,ou derivado farmaceuticamente aceitável do dito ativador ou ligando, na fabricação de um medicamento para o tratamento ou profilaxia de doença óssea permite, pela primeira vez, anabolismo ósseo para intensificar a deposição óssea em condições que podem beneficiar à deposição óssea aumentada. O inverso, onde há inibição e/ou retardamento de deposição óssea é também facilitado.
BR0108344-9A 2000-02-15 2001-02-15 Modulação de formação óssea BR0108344A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0003310.0A GB0003310D0 (en) 2000-02-15 2000-02-15 Bone formation
PCT/GB2001/000626 WO2001060355A1 (en) 2000-02-15 2001-02-15 Modulation of bone formation

Publications (1)

Publication Number Publication Date
BR0108344A true BR0108344A (pt) 2003-03-11

Family

ID=9885521

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0108344-9A BR0108344A (pt) 2000-02-15 2001-02-15 Modulação de formação óssea

Country Status (18)

Country Link
US (1) US20030139372A1 (pt)
EP (1) EP1259233A1 (pt)
JP (1) JP2003522787A (pt)
KR (1) KR20020093808A (pt)
CN (1) CN1430512A (pt)
AU (1) AU3212101A (pt)
BR (1) BR0108344A (pt)
CA (1) CA2399810A1 (pt)
CZ (1) CZ20022741A3 (pt)
GB (1) GB0003310D0 (pt)
HK (1) HK1049618A1 (pt)
HU (1) HUP0204511A3 (pt)
IL (1) IL151243A0 (pt)
MX (1) MXPA02007901A (pt)
NO (1) NO20023837L (pt)
NZ (1) NZ520764A (pt)
WO (1) WO2001060355A1 (pt)
ZA (1) ZA200206318B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716842B2 (en) 2002-04-05 2004-04-06 Warner-Lambert Company, Llc Antidiabetic agents
AU2003257854A1 (en) * 2003-05-28 2005-01-21 Eisai R&D Management Co., Ltd Compositions and foods and drinks contiaing higher fatty acid derivative
CA2528805A1 (en) * 2003-08-13 2005-05-06 Chiron Corporation Gsk-3 inhibitors and uses thereof
ES2378435T3 (es) * 2003-09-19 2012-04-12 Janssen Pharmaceutica N.V. �?cidos 4-((fenoxialquil)tio)-fenoxiacéticos y análogos
CN1882524B (zh) * 2003-09-19 2011-06-08 詹森药业有限公司 4-((苯氧基烷基)硫基)-苯氧基乙酸及类似物
EP1889613A4 (en) * 2005-05-27 2010-11-24 Shionogi & Co PHARMACEUTICAL COMPOSITION COMPRISING VITAMIN K
NO20053517L (no) * 2005-07-18 2007-01-19 Thia Medica As Anvendelse av lipidsenkende midler
CA2708391A1 (en) * 2007-12-13 2009-06-25 Sri International Ppar-delta ligands and methods of their use
US8168675B2 (en) * 2008-01-02 2012-05-01 Marin Bio Co., Ltd. Compositions and methods for treating neurodegenerative diseases
WO2010137944A1 (en) 2009-05-27 2010-12-02 N.V. Nutricia Treatment of hypercalcaemia
JP2015517087A (ja) * 2012-02-15 2015-06-18 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 骨障害を評価するための手段及び方法
US9763911B2 (en) 2013-12-12 2017-09-19 Mayo Foundation For Medical Education And Research Prostacyclin compositions for regulation of fracture repair and bone formation
CN105327333B (zh) * 2015-10-30 2018-09-07 大连大学 可促进牙种植体周围成骨的口腔施用组合物及其制剂
CN110433156A (zh) * 2019-08-27 2019-11-12 成都元素平衡生物科技有限公司 芝麻素在成骨分化中的新应用
US20220331267A1 (en) * 2019-09-05 2022-10-20 Rush University Medical Center Methods and compositions for treatment of demyelinating disorders
CN111789833A (zh) * 2020-08-31 2020-10-20 苏州大学 2-溴棕榈酸在制备防治骨丢失相关疾病的药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5312814A (en) * 1992-12-09 1994-05-17 Bristol-Myers Squibb Co. α-phosphonocarboxylate squalene synthetase inhibitors
EP0783888A1 (en) * 1995-12-26 1997-07-16 Sankyo Company Limited Use of troglitazone and related thiazolidinediones in the manufacture of a medicament for the treatment and prophylaxis of osteoporosis
JPH09295936A (ja) * 1996-04-30 1997-11-18 Kowa Techno Saac:Kk 人工透析患者の骨疾患治療用外用剤
US5804210A (en) * 1996-08-07 1998-09-08 Wisconsin Alumni Research Foundation Methods of treating animals to maintain or enhance bone mineral content and compositions for use therein
US5925657A (en) * 1997-06-18 1999-07-20 The General Hospital Corporation Use of PPARγ agonists for inhibition of inflammatory cytokine production
AU1143899A (en) * 1997-11-10 1999-05-31 Novo Nordisk A/S Transdermal delivery of 3,4-diarylchromans
GB9824614D0 (en) * 1998-11-11 1999-01-06 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
HK1049618A1 (zh) 2003-05-23
AU3212101A (en) 2001-08-27
GB0003310D0 (en) 2000-04-05
NO20023837L (no) 2002-10-14
EP1259233A1 (en) 2002-11-27
WO2001060355A1 (en) 2001-08-23
CN1430512A (zh) 2003-07-16
JP2003522787A (ja) 2003-07-29
NO20023837D0 (no) 2002-08-14
HUP0204511A3 (en) 2004-11-29
NZ520764A (en) 2004-05-28
HUP0204511A2 (en) 2003-05-28
MXPA02007901A (es) 2004-09-10
CA2399810A1 (en) 2001-08-23
CZ20022741A3 (cs) 2003-03-12
US20030139372A1 (en) 2003-07-24
ZA200206318B (en) 2003-11-07
IL151243A0 (en) 2003-04-10
KR20020093808A (ko) 2002-12-16

Similar Documents

Publication Publication Date Title
BR0108344A (pt) Modulação de formação óssea
MX9203444A (es) Medicamentos.
BR0115474A (pt) Composição e método para inibição da transmissão de hiv que usam 6-benzil-4-oxopirimidinas substituìdas aplicada por via tópica
BR9809968A (pt) Aplicação de derivados tiazolidinadiona no tratamento da pcos e diabetes gestacional
NO20034986D0 (no) Furan og tiofenderivater som aktiverer human peroksisom proliferator aktiverte reseptorer
EA200700232A1 (ru) Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения
BR0009864A (pt) Composto, composição farmacêutica, métodos para o tratamento de doenças, para o tratamento e/ou prevenção de condições mediadas pelos receptores nucleares e para o tratamento e/ou prevenção de diabete e/ou obesidade, e, uso de um composto
BR0213079A (pt) Forma de dosagem para o tratamento da diabetes mellitus
AR035927A1 (es) Compuesto de lactama (n)-((s)-2-hidroxi-3-metilbutiril)-1-(l-alaninil)-(s)-1-amino-3-metil-4,5,6,7-tetrahidro-2h-3-benzazepin-2-ona , composicion farmaceutica que lo comprende, procedimiento para la inhibicion de la liberacion de peptido b-amiloide y/o su sintesis que lo emplea y su uso para la fabr
CO4340681A1 (es) Procedimientos de uso para la inhibicion de la perdida osea y la disminucion del colesterol en suero
DE60124684D1 (de) Sulfonamido-substituierte verbrückte bicycloalkylderivative
ATE440599T1 (de) (+)-2-ä1-(3-ethoxy-4-methoxyphenyl)-2- methylsulfonylethylü-4-acetylaminoisoindolin-1, - dion zur verwendung in der behandlung von psoriasis durch orale verabreichung
BR0112476A (pt) Uso de agonistas do receptor d2/d3 de dopamina para tratar fibromialgia
BR0111913A (pt) Análogos de gabapentina para distúrbios do sono
BR0113389A (pt) Compostos que inibem a atividade do fator xa
PA8542901A1 (es) Uso de (z)-2-ciano-3-hidroxi-but-2-acido enoico-(4-trifluorometilfenil)-amida para tratar la esclerosis multiple
BR0013126A (pt) Uso de um agente quelante quìmico, derivado de ciclofano, kit para a provisão de bloqueio neuromuscular e de sua reversão, e, método para reverter o bloqueio neuromuscular induzido por droga em um paciente
BR0113590A (pt) 7-oxo-piridopirimidinas
BR9909872A (pt) uso de dexmedetomidina para uma unidade de sedação de proteção intensiva
BR9911067A (pt) Uso de inibidores de receptores de alfa1beta1 integrina e inibidores tgf-beta1 no tratamento de doença renal
BR9811473A (pt) Infecção por rinovìrus inibida por óxido nìtrico
AR023687A1 (es) Una composicion para el tratamiento de desordenes de la retina externa y el uso de un antagonista de glutamato para la manufactura de un medicamento parael tratamiento de desordenes de la retina externa
DE60128100D1 (de) Analgetisches arzneimittel
AR035006A1 (es) Derivado de naftiridin-dibenzo[a,d]ciclohepteno-10-acetico, composicion farmaceutica, y el uso de dicho derivado para la fabricacion de un medicamento.
BRPI0516115A (pt) compostos arilsulfonilmetil ou arilsulfonamida aromáticos substituìdos adequados para tratar distúrbios que respondem à modulação do receptor de dopamina d3

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6O, 7O E 8O ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2016 DE 25/08/2009